Haleon PLC Commencement of On-Market Share Buyback Programme

RNS Number : 7537Y

Haleon PLC

01 August 2024

 

 

Haleon plc: Commencement of On-Market Share Buyback Programme

 

1 August 2024: Haleon plc (the "Company", or "Haleon") announces that, as set out in the 2024 Half year results announcement released today, it is commencing a share buyback programme to purchase ordinary shares of £0.01 each in the Company (the "Shares") up to an aggregate consideration of £185 million (the "Buyback Programme"), in line with its stated capital allocation priorities.

 

The Buyback Programme represents the remainder of the £500 million allocated to share buybacks in 2024 announced on 29 February 2024, following completion of the off-market purchase of Shares from Pfizer Inc. announced on 21 March 2024. All Shares purchased by the Company under the Buyback Programme will be cancelled. The purpose of the Buyback Programme is to reduce share capital and is in line with the Company's capital allocation priorities.

 

The Company has entered into an arrangement with HSBC Bank plc ("HSBC") for the purchase by HSBC (acting as principal) of the Shares through daily instructions that may be provided by Haleon during the Buyback Programme. Under the Buyback Programme, Haleon will, subject to applicable law and regulation, have discretion as to whether to provide a daily instruction to HSBC. No daily instructions will be provided by Haleon during its closed periods.

 

The Buyback Programme commences today and will end no later than 31 December 2024. Under the terms of the Buyback Programme, any purchase of Shares by HSBC will be carried out on the London Stock Exchange.

 

There is no guarantee that the Buyback Programme will be implemented in full or of the number of Shares that will be bought back by the Company. The Company will make further regulatory announcements in respect of purchases of Shares under the Buyback Programme as they occur.

 

Notes

The maximum number of Shares that may be purchased under the Buyback Programme is 913,000,000, being the number of Shares the Company is authorised to purchase pursuant to its general authority to make market purchases granted at its Annual General Meeting held on 8 May 2024 (the "AGM Authority"). To date, no Shares have been purchased pursuant to the AGM Authority.

 

Any purchases of Shares contemplated by this announcement will be effected within certain pre-set parameters. The Buyback Programme will operate in accordance with (i) the AGM Authority; (ii) the assimilated UK Market Abuse Regulation No. 596/2014 and assimilated Commission Delegated Regulation (EU) 2016/1052 (in each case as they form part of law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018) and (iii) Chapter 9 of the UK Financial Conduct Authority's UK Listing Rules.

 

Enquiries
Investors		Media
Sonya Ghobrial	[phone]	Zoë Bird	[phone]
Rakesh Patel	[phone]	Gemma Thomas	[phone]
Emma White	[phone]
Email: [e-mail]		Email: [e-mail]

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCEAKPFEEDLEEA